The global dyslipidemia drugs market to grow at a CAGR of 5.27% during the period 2017-2021.
The report, Global Dyslipidemia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
According to the report, one driver in the market is increasing risk of CVDs. Elevated levels of cholesterol in the blood lead to the deposition of cholesterol in the arterial walls, which results in atherosclerosis, hardening and narrowing the arteries. The resultant narrowing of blood vessels decreases the blood flow to the heart muscles, causing a heart attack. High cholesterol levels account for nearly one-third of all ischemic heart diseases and hence, remain a significant cause of ischemic heart diseases and strokes in developed and developing countries such as India and China. Data estimates suggest that among men aged 40 years and over, a 10% decrease in serum cholesterol levels reduces the risk of heart disease by 50% within five years.
Hence, cardiovascular risk management guidelines by authorities such as the American College of Cardiology and American Heart Association consider reducing blood cholesterol an important factor in reducing cardiovascular risk. As cholesterol disorder is one of the major causes for CVDs, patients try to strictly adhere to cholesterol maintaining drugs to avoid the occurrence of CVD. This preventive approach toward the occurrence of CVDs will further boost the sales of cholesterol controlling agents.
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: An overview of dyslipidemia
PART 06: Pipeline analysis
PART 07: Market landscape
PART 08: Market segmentation by drug class
PART 09: Geographical segmentation
PART 10: Decision framework
PART 11: Drivers and challenges
PART 12: Market trends
PART 13: Vendor landscape
PART 14: Key vendor analysis
For more information about this report visit http://www.researchandmarkets.com/research/v6dd2m/global